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An effective therapeutic approach against cancer typically requires the combination of
several modalities, such as chemotherapy, radiation, and hyperthermia. In this regard, the
development of multifunctional nanomaterial-based systems with combined therapeutic and
molecular imaging capabilities has shown great potential but has not been fully explored. In
particular, magnetic nanomaterials have been at the fore-front of cancer research as
noninvasive imaging probes as well as multifunctional therapeutics. [1] For example,
magnetic nanoparticles (MNPs) with appropriate surface modifications have been
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successfully applied to deliver therapeutic biomolecules, such as anticancer drugs,
antibodies, and siRNAs, to target tumor cells or tissues. [2] Moreover, the unique physical
and chemical properties of these magnetic nanostructures have enabled their wide
applications in cancer imaging and therapy, including magnetic resonance imaging (MRI)
and hyperthermia. [3] Promising advances have been made in synthesizing multifunctional
MNPs from various materials, including metals, [4] metal oxides, [5] metal alloys, [6] and
metal–graphitic-shell nanomaterials, [7] with different properties. However, current studies
are mostly focused on the synthesis and characterization of materials with limited
demonstration of their biomedical applications, like molecular imaging and therapy. As a
result, research efforts towards developing MNP-based multimodal therapeutics to control
the tumor microenvironment are highly limited and have not been fully explored. Therefore,
in order to address the challenges of MNP-based therapeutics, as well as to narrow the gap
between current nanoparticle-based multimodal imaging approaches and their clinical
applications, there is a clear need to synthesize effective chemotherapeutic MNPs and to
develop multimodal therapies for targeting specific oncogenes, thereby activating/
deactivating corresponding key signaling pathways.
In this Communication, we describe the novel synthesis and a systematic in vitro evaluation
and application of multifunctional magnetic nanoparticles (MNPs) with an iron cobalt core
and a graphitic carbon shell (FeCo/C) for the targeted delivery of small interfering RNA
(siRNA) to tumor cells with a concomitant hyperthermia-based therapy, thereby
cooperatively inhibiting proliferation of and inducing apoptosis in tumor cells (Figure 1). In
parallel, we also demonstrate that our MNPs can be used as highly sensitive magnetic
resonance and Raman imaging probes. As a model study, we used glioblastoma multiforme
(GBM) cell lines, the most malignant and difficult-to-treat brain tumor cells. We
hypothesized that the targeted delivery of our siRNA–MNP constructs against the oncogenic
receptor (EGFRvIII) and subsequent hyperthermal treatment would selectively, as well as
cooperatively, damage the tumor cells, resulting in the synergistic inhibition of tumor-cell
proliferation and the induction of apoptosis via the deactivation of the PI3K/AKT signaling
pathway. Hence, these MNP-based therapeutics could potentially be used for the
simultaneous imaging and therapy of malignant tumors both in vitro and in vivo.
Recent efforts in cancer therapy have demonstrated the application of hyperthermia, which
involves localized heating of cancerous cells or tissues, as an adjuvant to chemotherapy and
radiation to improve their efficacy. [8] Hyperthermia typically involves increasing the local
temperature of the tumor region to 42–46 ° C over a given time period, ultimately resulting
in apoptosis of the heat-sensitized cancer cells. [9] One of the best methods of achieving a
localized hyperthermal effect is to deliver MNPs to the target cells and subsequently apply
electromagnetic fields following their cellular uptake/localization. [10] Furthermore,
hyperthermia and its downstream effects can be significantly enhanced by the concomitant
use of other cancer therapies, including radiation and drug/gene delivery and vice versa.
To develop cooperative (hyperthermia and siRNA delivery) therapeutic systems based upon
MNPs, we synthesized graphitic-carbon-protected iron cobalt (FeCo/C) nanoparticles (7 and
11 nm in diameter) with a body-centered cubic (bcc) crystalline structure using
hydrothermal synthetic methods followed by an annealing process at 1000 °C.
Highresolution transmission electron microscopy (HR-TEM) and X-ray diffraction (XRD)
confirmed the excellent chemical/physical properties of our FeCo/C NPs, such as
monodispersity, narrow size distribution of the nanoparticles, and the presence of a
crystalline bcc FeCo core (Figure 2). The graphitic-carbon shells surrounding the FeCo core
were confirmed by Raman spectroscopy analysis and HR-TEM. Furthermore, the thickness
of the graphitic-carbon coating could be monitored by the intensity of the Raman signal
(marked by arrows in Figure 2d). We also characterized the magnetic properties of our
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FeCo/C NPs using a superconducting quantum interference device (SQUID). Our FeCo/C
NPs were found to display remarkable superparamagnetic properties at room temperature, as
suggested by the significantly higher value of the saturation magnetization (Ms for our
FeCo/C NPs as compared to that of the commercially available Fe3O4 (Figure 2e). This was
attributed to the higher magnetic moments of the FeCo/C NPs as a result of the high-
temperature annealing, as shown in Figure S2 in the Supporting Information (SI).
In this work, our FeCo/C MNPs have several advantages over other conventional magnetic
nanoparticles, such as FePt, Fe2O3, and Fe3O4: i) FeCo exhibits an excellent magnetization
value (e.g., 11-nm FeCo ≈235 emu g−1), has a high Curie temperature, and has high
magnetic anisotropy energies, all of which are critical in order to enhance their potential for
biomedical applications, such as MRI and hyperthermia; ii) the thickness of the outer
graphite-shell layers can be controlled by our synthetic method, which would lead to an
improved Raman signal intensity for detecting cancerous cells; and iii) the nanoparticles are
chemically inert due to the presence of a graphitic carbon shell [11] and can be made
biocompatible by appropriate surface modifications (e.g., dextran-ligand coating).
Moreover, compared to conventional methods [1b,12] for the synthesis of core–shell metal-
alloy magnetic nanomaterials, such as electric-arc discharge, [13] high-temperature thermal
decomposition, [14] and chemical vapor deposition (CVD), [11] our novel hydrothermal
synthetic approach has several advantages, such as relatively milder synthetic conditions,
low environmental impact, cost effectiveness, ease of scalability (see Figure S3 in the SI),
and the exclusion of toxic solvents and size-separation techniques.
Another critical step to realize the full potential of our multimodal FeCo/C NPs for in vitro/
in vivo biomedical applications (e.g., targeted drug/gene delivery, MRI, or hyperthermal
therapy) is to make the nanoparticles biocompatible and modify the surface for achieving
target-specific intracellular delivery. [15] Several strategies, including coating with
molecules such as dextran, have been successfully used for functionalizing magnetic
nanoparticles and rendering them biocompatible. [16] Hence, we synthesized a series of
dextran derivatives (see Figure S4a in the SI) and used them to coat our FeCo/C NPs (see
Figure S4b in the SI). The dextrancoated FeCo/C NPs were found to have excellent colloidal
stability and the hydro-dynamic diameter was found to be ≈150nm (see Figures S5 and S6
in the SI). These dextran-modified FeCo/C NPs were then conjugated to specific cancer-
targeting biomolecules, such as epidermal growth factor receptor (EGFR) antibodies and
cyclic-RGD (c-RGD) peptide, to target glioblastoma cells and to improve their intracellular
uptake. The conjugation of biomolecules such as EGFR antibodies and c-RGD to our FeCo/
C NPs not only increases transfection of our nanoparticles via receptor-mediated
endocytosis but can also selectively target the glioblastoma cells by binding to receptors
(EGFR and integrins) known to be overexpressed in glioblastoma cells. [17]
Highly sensitive multimodal imaging tools like MRI, computed tomography (CT), positron-
emission tomography (PET), and Raman imaging, which rely on nanomaterials as molecular
probes, have gained much attention as diagnostic tools for specific cancers, such as breast
and brain cancers. [18] In order to investigate the capability of our FeCo/C NPs as
multimodal imaging nanoprobes, we focused on two important imaging methods for cancer,
in vivo MRI and in vitro Raman imaging, both of which provide complementary
information about tumor microenvironments at the tissue level and/or cellular level. [3b,18b]
In order to test the capability of our MNPs as MRI contrast agents, the transverse relaxation
times (T2) of the water protons were measured in a specific magnetic field and their values
were compared to those of the commercially available MRI contrast agent Resovist (Fe3O4,
from Roche). Both the 7- and 11-nm FeCo/C NPs exhibited a higher relaxivity coefficient
(r2, 252 and 392 m M−1 s−1, respectively) and enhanced T2-weighted MR contrast (Figure
3a,b) as compared to Resovist (r2 = 140 m M−1 s−1). Characterization of our biocompatible
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dextran-coated FeCo/C NPs as in vivo MRI agents was performed by injecting the MNPs
into a rat’s tail vein. Preliminary MRI studies showed that our nanoparticles accumulated in
the liver, spleen, and kidneys and their imaging contrast was significantly higher (about 10
times) than that of Resovist (Figure 3c). We also monitored the in vivo biodistribution and
MRI contrast of these FeCo/C NPs over 10 days. It was found that the NPs were retained in
the liver and spleen and that there was no significant loss of imaging contrast over this time
period (see Figure S7 in the SI). Furthermore, the analysis of in vitro Raman imaging
results, wherein confocal microscopy was used to observe the NP-internalized U87 cell
lines, confirmed that the intensity of the D and G bands of the graphitic-carbon shells was
indeed proportional to the thickness of the carbon shells on the FeCo/C NPs (Figure 3d).
This data strongly suggests that our FeCo/C NPs have a well defined correlation and
sensitive response when used as Raman imaging probes at the single-cancer-cell level.
These preliminary in vitro and in vivo studies showed no visible cytotoxicity due to the
degradation of the FeCo/C NPs. It has been reported that FeCo/C NPs are safely excreted
over time through the biliary system after being taken up by the liver and spleen. [19] Hence,
it is highly unlikely that these FeCo/C NPs would pose any serious toxicity issues when used
in vivo. A detailed toxicological evaluation of these MNPs in animal models would be
forthcoming in the future.
Having demonstrated the potential of our FeCo/C NPs as multimodal imaging probes, we
then focused on evaluating their ability to be used as targeted hyperthermia agents for tumor
therapy in vitro. We hypothesized that our FeCo/C NPs would be more efficient
hyperthermia agents than Fe3O4 NPs of similar size due to their high magnetization and
therefore would be more effective in inhibiting proliferation and inducing apoptosis of target
brain tumor cells (bTCs). To test their efficacy as targeted hyperthermia agents, we first
measured the minimum time required to attain the therapeutic temperature (≈43 °C) when
placed in a homogeneous magnetic field. The specific absorption rates (SARs) of FeCo/C
and Fe3O4 NPs (≈69 W g−1 for FeCo/C and 13 W g−1 for Fe3O4), as derived from the plots
of temperature versus time in aqueous solutions under a 334 kHz magnetic field (which is
the optimum frequency range estimated by the Neel and Brownian relaxation-time
simulations [20]), indicated that the time required for our FeCo/C NPs to reach the
therapeutic temperature was ten times shorter than that of Fe3O4 NPs (see Figure S9 in the
SI). We next evaluated the concentration-dependent cytotoxicity of our FeCo/C NPs by
serial-dilution investigations. From this study, the range of concentrations inducing
negligible cytotoxic effects on cells was identified and the concentrations (95% cell viability
at 300 μg mL−1 after ≈ 24 h post transfection) within this range were used for our
subsequent experiments (see Figure S10 in the SI). We then sought to precisely increase the
temperature of tumor cells while minimizing the exposure of other cells to hyperthermic
temperatures. For this purpose, FeCo/C NPs functionalized with c-RGD peptide or EGFR
antibodies were incubated in cocultures of glioblastoma cells (U87–EGFP), which had been
genetically labeled with enhanced green fluorescent protein (EGFP) and present EGFRs on
their membranes and several other less tumorigenic cells, such as PC-12 and astrocytes,
which tend to have low expression levels of integrins and EGFRs. Our data clearly indicates
that the surface modification of our FeCo/C NPs with c-RGD peptide or EGFR antibodies
resulted in their selective cellular uptake by the target bTCs, as compared to PC-12 or
astrocytes (see Figure S11 in the SI). Following intracellular uptake of the aforementioned
NP constructs, the cells were exposed to an alternating current (AC) magnetic field for 15
min. Significant inhibition of proliferation and hyperthermia-induced cell death was
observed mainly in the U87 cells while the less-tumorigenic PC-12 cells largely continued
proliferating with time (Figure 4a,b).
In the past decade, there has been considerable interest in the development of nanoparticle-
based siRNA-delivery methods for cancer therapy. RNA interference (RNAi) involves the
Park et al. Page 4
Small. Author manuscript; available in PMC 2011 September 27.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
use of siRNAs to selectively mediate the cleavage of complementary mRNA sequences and
thus regulate target gene expression. [21] In combination with other chemotherapeutic
methods like hyperthermia, RNAi could prove to be a powerful tool to manipulate the tumor
microenvironment. In order to deliver siRNA to the target cells, the FeCo/C NPs were
conjugated to the siRNA using polyethyleneimine (PEI) as a cationic polymer via a layer-
by-layer approach [22] (see Figure S13 in the SI). We initially optimized the knockdown
efficiency of our siRNA–FeCo/C NP construct by the suppression of EGFP in U87–EGFP
cells. The decrease in green fluorescence intensity due to siRNA-mediated knockdown of
EGFP was monitored to assess the knockdown efficiency (≈ 80% after 3 days of
transfection) of our siRNA–NP constructs (see Figure S14 in the SI). Once the conditions
for the siRNA delivery and knockdown were optimized, we focused on inhibiting the
proliferation and inducing apoptosis of U87–EGFRvIII cell lines overexpressing the
oncogenic EGFRvIII gene. EGFRvIII is a mutant type of EGFR as well as an oncogenic
receptor that is highly expressed only in tumor cells, and not in normal cells. [23] The effect
of the knockdown of the EGFRvIII oncogene using our siRNA–FeCo/C NP constructs was
assessed using a microscope at 96 h post transfection (see Figure S14 in the SI). We
hypothesized that the knockdown of the target oncogene, EGFRvIII, with our
multifunctional siRNA–FeCo/C NP constructs, combined with hyperthermia, would lead to
a cooperative inhibition of tumor-cell proliferation and increase in cell death. The U87–
EGFRvIII cells were incubated with our FeCo/C NPs modified with siRNA against
EGFRvIII, followed by hyperthermia treatment for 5 min at 72, 96, and 120 h post siRNA
treatment. Quantitative analysis based upon the 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium assay, commonly known as the
MTS assay (Figure 4c) showed that treatment of cells with our siRNA–MNPs against
EGFRvIII followed by hyperthermia induced significantly more cell death as compared to
the controls. This could be attributed to the fact that silencing of the EGFRvIII oncogene
results in a decrease in expression of the focal adhesion proteins that make the cells more
susceptible to heat, thereby leading to a synergistic increase in cell death. [24] Our study
clearly demonstrates that the appropriate combination of various therapeutic modalities
using our FeCo/C NPs can significantly enhance the therapeutic efficacy relative to the
individual components.
In summary, this work provides an early demonstration of integrating multimodal imaging
with combined hyperthermia and siRNA-based therapy in malignant tumor cells using
highly efficient FeCo/C NPs. Our FeCo/C NPs have successfully been demonstrated to have
a well defined correlation and a fast and sensitive thermal response to the strength of the
applied magnetic field. At the same time, our FeCo/C NPs could be developed as novel
therapeutic and diagnostic tools for cancer research. The ability to functionalize the graphitic
surface of the FeCo/C NPs with targeting ligands and biomolecules would be critical to
realize the potential of nanoparticle-based diagnosis and therapy of various cancers. It
should be noted that our FeCo/C NPs showed excellent MRI contrast results compared to
the conventional MRI contrast agents as well as enabling us to collect the Raman spectral
information at the single-cell level. More importantly, the use of our FeCo/C NPs for site-
specific and localized hyperthermia in conjunction with siRNA therapy against oncogenes
would greatly complement and enhance the effects of other therapeutic modalities, including
gene therapy and chemotherapy, thereby reducing the dose of anticancer drugs, mitigating
their toxic side effects, and effectively circumventing drug resistance in cancers.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Magnetic FeCo–graphite nanoparticles for multimodal imaging and targeted tumor therapy.
a) Detailed structure of the MNPs depicting the highly magnetic FeCo core, protective
Raman-active graphite shell, and the biocompatible dextran coating. b) Inhibition of
proliferation and induction of apoptosis via combined siRNA delivery and hyperthermia
using siRNA–FeCo/C NP constructs.
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Figure 2.
Structural and magnetic properties of the FeCo/C nanoparticles. a) TEM image of the 11-nm
nanoparticles (scale bar = 20 nm). b) HR-TEM image of the nanoparticles showing the
crystalline lattice structure of the FeCo core. c) Powder XRD for the 7- and 11-nm
nanoparticles showing the presence of a bcc crystalline core and graphitic shell. d) Raman
spectrum (excitation at 632.8 nm) of the 11-nm nanoparticles with single and multiple
carbon shells (marked by arrows) showing the D and G bands of graphitic carbon (scale bar
= 2 nm). e) Room-temperature magnetization versus applied magnetic field for 11-nm FeCo/
C NPs (red symbols) and Fe3O4 (black symbols). Note that no hysteresis loop exists owing
to the superparamagnetism of the nanoparticles.
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Figure 3.
MR measurements and imaging of FeCo/C NPs and Resovist. a) Concentration-dependent
T2 measurements of FeCo/C NPs and Resovist solutions. b) T2-weighted MR images of
various nanoparticle solutions. The FeCo/C NPs show higher MR image contrast (several
fold) as compared to Resovist, a traditional MRI contrast agent. c) T2-weighted MR images
of a rat before (t = 0 min) and 30 min after (t = 30 min) injection of FeCo/C NPs (left) and
Resovist (right) into a rat’s tail vein. The nanoparticles were seen to localize in the liver
(green arrow), spleen (blue arrow), and kidneys (red arrow) of the animal. Also, FeCo/C
NPs show a higher imaging contrast at a lower concentration (0.25 mg of Fe) as compared to
Resovist (2.5 mg of Fe). d) Raman spectra of U87-EGFP cells (marked by arrows) treated
with 11-nm FeCo/C NPs. The spectra shows the capability of the FeCo/C NPs to be used as
imaging agents at the single-cell level (see Figure S8 in the SI for detailed Raman imaging).
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Figure 4.
In vitro hyperthermia and siRNA-delivery studies of the FeCo/C NPs. a,b) U87–EGFP cell
death induced by hyperthermia in cocultures of the highly tumorigenic U87–EGFP cells
(marked by arrows) and the less-tumorigenic PC-12 cells (marked by arrows) via the
targeted delivery of FeCo/C NPs to the U87 cells. Fluorescence images (a) and quantitative
analysis (b) show that significant hyperthermia-induced cell death is observed in U87 cells,
while the PC-12 cells keep proliferating with time. (Note that the number of cells at 0 h was
taken to be 100% and the cell counts at other time points were normalized to this value.)
Annexin V assays for detection of early apoptosis proved that the cell death was caused by
localized hyperthermia-induced apoptosis rather than necrosis (see Figure S12 in the SI). c)
MTS assay demonstrating the synergistic inhibition of proliferation and induction of cell
death by the combined siRNA and hyperthermia treatment using siRNA-FeCo/C NPs in
U87–EGFRvIII cells as compared to individual treatments and nontreated controls. The
scale bar in all images is 100 μm.
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